In the Life organization, we established the business vision "We will lead the world in advancing Bio Industrial Autonomy and contribute to a future embracing global harmony" with the aim of clarifying future developments of the business, its scope and direction. In this vision, we have targeted the "Pharmaceutical, Food, Beverage & Biotech" sectors and aim to further expand our business, centering on these industries, by taking advantage of our strengths in "Measurement, Imaging, Analysis, Diagnosis, Integration" and Yokogawa core technologies.
By contributing to the development of measurement and analysis technologies, we will solve problems that limit research progress and create a world where scientists can concentrate on science.
Using real-time monitoring and software innovations, we will create a virtual world of "Digital Twin" where experimental simulations are leveraged to realize precision predictive control
We analyze and control the information obtained from all manufacturing activities and solve issues related to raw material quality, facility degradation, transmission of technology, and production processes to improve work environment and worker safety.
In addition to improving optimal and efficient automatic processes based on demand forecasting, we will assist with quality improvements that include taste attributes, and promote autonomous operation that grows independent of human intervention.
Water & Wastewater
Yokogawa supports a wide range of water control applications in both the municipal and industrial water markets.
YOKOGAWA is working on the development of single cell mass spectrometry and single cell gene analysis. In order to analyze one cell with high sensitivity, we are developing a method of collecting target cells while keeping position information under observing cells with confocal scanner.
Yokogawa is contributing to the development of the pharmaceutical industry based on its performance of introducing over 1,000 systems in the areas of drug substances, pharmaceutical products, and biotechnology.
In addition to daily improvement cycles, Yokogawa will use IIoT to support create environments that do not cause defects and that are designed to completely reduce losses.
Life Business Headquarters’ contribution towards the fight against Novel Coronavirus Disease (COVID-19)
Yokogawa established the Life Business Headquarters with the goal of promoting well-being for all. In addition to engaging in our existing life science and manufacturing solutions businesses targeting the pharmaceutical and food industries, the headquarters works to develop new products and services and provides one-stop solutions that revolutionize productivity throughout the pharmaceutical and food industry value chain, from basic research to manufacturing, logistics, and services.
Yokogawa has more than 30 years’ experience in the life science field. The CSU spinning disk confocal scanner series is our core strength, and over 3,000 units have been sold globally. Other products, including a live cell imaging system, a high-content analysis system and single cell analysis solution also support leading life science studies. In the field of manufacturing solutions, over 1,000 Yokogawa manufacturing, production, and quality management systems and control systems have been introduced in the pharmaceutical industry.
In response to the novel coronavirus (COVID-19), Yokogawa has been taking various measures to prevent transmission of the virus while working to minimize the impact on customers. We are also contributing to the fight against COVID-19 by collaborating with research institutes globally and supporting research to develop new medication or vaccines. Yokogawa will continue to work with customers and business partners in an effort to resolve the crisis society is facing.
Please contact our sales and service representatives if you have any interest in our products, or you can send inquiries from the form below.
Yokogawa Develops Single Cellome System SS2000 for Intracellular Sampling
＜Features of the SS2000＞
The SS2000 will be released to the Japan, US and China market in January 2022, with release in other markets such as Europe to follow at a later date.
Yokogawa Acquires Insilico Biotechnology, Developer of Innovative Bioprocess Digital Twin Technology
Yokogawa Electric Corporation acquires Insilico Biotechnology a developer and provider of bioprocess software and services.
Sales release : Advanced Control Bioreactor System BR1000 was released.
YOKOGAWA Sponsored Webinar
Bioprocessing Summit 2020 Virtual
Dates: August 24-28 EST, 2020
Yokogawa introduce about advanced automated bioreactor controller system. Join us at our virtual tradeshow booth. We look forward to connecting with you.
Discovering Potential Covid-19 Therapies using High Content Screening
YOKOGAWA Sponsored Webinar
July 29, 2020 11 am to 12 pm EDT (July 30, 2020 0 am to 1 am JST)
Integration of soft-sensor technologies with CHO-cell predictive models for improved bioreactor automation & process control
BIO Digital 2020
June 8-12, 2020
We will participate in partnering event and hold a corporate seminar about Advanced Control Bioreactor System.
This application note will introduce the features of the SU10 and provide examples demonstrating the delivery of genome editing tools (Cas9 RNP) using the technology.
Yokogawa Enters into Capital and Business Alliance with GlyTech, Inc., a Leader in the Application of Glycan Technologies
Partnering to build biosynthesis processes and a pharmaceutical production platform
- Collaboration to widen use of N-NOSE cancer screening test -
- Supporting drug development research through the use of HCA and three-dimensional culture models -
Yokogawa Releases OpreX Environmental Monitoring System for Pharmaceutical and Medical Device Industries
- A system that ensures compliance with industry regulations and decreases risk to improve efficiency -
- Low invasiveness enables single-cell injection of target substances and extraction of intracellular materials -
Looking for more information on our people, technology and solutions?Contact Us